Peter Lio, MD

Articles by Peter Lio, MD

Treatment Selection of JAK Inhibitors for the Management of AD

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

December 12th 2023

Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.

Contraindications for Use of JAK Inhibitors in AD

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

December 12th 2023

Peter Lio, MD, reviews the contraindications of JAK inhibitors in AD and approaches for monitoring patients who are prescribed a JAK inhibitor.

Boxed Warnings for JAK Inhibitors in AD

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

December 5th 2023

Alexandra Golant, MD, comments on the boxed warnings on all currently approved JAK inhibitors, as well as the commonly used treatments in dermatology that have boxed warnings.

Safety of JAK Inhibitors Approved for AD Treatment

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

December 5th 2023

Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.

Indications and Efficacy of JAK Inhibitors for AD

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

November 28th 2023

Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.

Differentiating JAK Inhibitors From Other Therapies in AD

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

November 28th 2023

Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.

Targeting the JAK-STAT Pathway in AD

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

November 21st 2023

Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.

Intro to Janus Kinase (JAK) Inhibitors for Treatment of Atopic Dermatitis (AD)

ByChristopher G. Bunick, MD, PhD,Peter Lio, MD ,Lisa Swanson, MD, PhD,Alexandra K. Golant, MD

November 21st 2023

Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).

Impact of Dupilumab on Quality of Life for Atopic Dermatitis Patients

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 19th 2023

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Efficacy and Reported Outcomes With JAK Inhibitors in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 19th 2023

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

Ideal Candidates for Ruxolitinib Treatment of Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 12th 2023

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Safety Profile of Topical Ruxolitinib in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Aaron S. Farberg, MD,Alexandra K. Golant, MD

May 12th 2023

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Clinical Trials of Topical Ruxolitinib in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 5th 2023

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.

Overview of JAK Inhibitors in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

May 5th 2023

Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.

Assessing Severity of Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 28th 2023

Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.

Treatment Approach to Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 28th 2023

Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.

Traditional Steroids vs Emerging Therapies in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 21st 2023

Alexandra Golant, MD, comments on the adverse events of systemic therapies and how emerging nonsteroidal agents have a better safety profile in atopic dermatitis.

Treatment Landscape in Atopic Dermatitis

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 21st 2023

Matthew Zirwas, MD, highlights therapies that are available for the treatment of atopic dermatitis, including corticosteroids, calcineurin inhibitors and JAK inhibitors.

The Impact of Atopic Dermatitis on Quality of Life

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 14th 2023

Expert dermatologists review the impact of atopic dermatitis on quality of life for both the patient and their families.

An Overview of Atopic Dermatitis (AD)

ByLinda Stein Gold, MD,Matthew Zirwas, MD,Peter Lio, MD ,Alexandra K. Golant, MD,Aaron S. Farberg, MD

April 14th 2023

Peter A. Lio, MD, provides an overview of the pathophysiology of atopic dermatitis (AD) and the comorbidities often associated with it.

Keeping Physicians Up to Date With AD Advances

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Experts in dermatology share advice on helping fellow physicians stay apprised of the advances in AD and treat their patients more effectively.

Emerging Treatment Options in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Expert dermatologists consider ongoing trials and emerging treatment options for the management of AD.

Guidance for Topical Treatment Use Based on BSA in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.

Monitoring AD Treatments in Various Age Groups

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 8th 2023

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.